These trials are specifically focused on adult patients with membranous nephropathy who have anti-PLA2R antibodies (NCT04145440, NCT04733040) and patients with membranous nephropathy who have not responded to anti-CD20 targeted therapy (NCT04893096). This evidence concerns the gene PLA2R1 and membranous glomerulonephritis.